Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Index
RUT
Market Cap
227.23M
Enterprise Value
12.76M
Income
-16.15M
Sales
0.00M
Book/sh
2.93
Cash/sh
2.41
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
202
IPO
Feb 18, 2015
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
0.69
P/C
0.84
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
7.25
Current Ratio
7.26
Debt/Eq
0.17
LT Debt/Eq
0.16
Option/Short
Yes / Yes
EPS (ttm)
-0.16
EPS next Y
-1.50
EPS next Q
-0.40
EPS this Y
92.12%
EPS next Y
-847.86%
EPS next 5Y
12.63%
EPS past 3/5Y
14.88% 4.46%
Sales past 3/5Y
- -
EPS Y/Y TTM
93.49%
Sales Y/Y TTM
-
EPS Q/Q
3.97%
Sales Q/Q
-
Insider Own
5.57%
Insider Trans
-3.87%
Inst Own
87.47%
Inst Trans
1.09%
ROA
-4.10%
ROE
-5.04%
ROIC
-4.26%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-14.09%
SMA50
-20.63%
SMA200
-39.43%
Trades
Shs Outstand
111.39M
Shs Float
105.44M
52W High
5.45 -62.66%
52W Low
2.03 0.25%
Volatility
8.89% 7.98%
ATR (14)
0.19
RSI (14)
33.12
Beta
0.53
Rel Volume
1.66
Avg Volume
1.86M
Volume
997,994
Perf Week
-11.52%
Perf Month
-11.90%
Perf Quarter
-42.35%
Perf Half Y
-31.25%
Perf YTD
-42.02%
Perf Year
-28.35%
Perf 3Y
-90.75%
Perf 5Y
-92.70%
Perf 10Y
-92.11%
Prev Close
2.11
Price
2.04
Change %
-3.55%
Consensus
Buy
Avg. Price Target
$8.31
Implied Upside
+308.4%
Analysts14incl. previous ratings
Rating Distribution7 Buy · 6 Hold · 1 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 08, 2026Upgrade
GS logoGGoldman
Sell → Neutral$4+96.6%
Sep 16, 2026Upgrade
NNeedham
Hold → Buy$9+342.3%
Sep 01, 2026Resumed
CChardan Capital Markets
Buy$11+440.5%
Nov 18, 2025Downgrade
JPM logoJJP Morgan
Neutral → Underweight
Aug 20, 2025Upgrade
BAC logoBBofA Securities
Neutral → Buy$10+391.4%
Jul 25, 2025Downgrade
BAC logoBBofA Securities
Buy → Neutral$4+96.6%
May 30, 2025Downgrade
EVR logoEEvercore ISI
Outperform → In-line$5+145.7%
May 28, 2025Downgrade
MS logoMMorgan Stanley
Overweight → Equal-Weight$7+244.0%
May 28, 2025Downgrade
LLeerink Partners
Outperform → Market Perform$8+293.1%
May 28, 2025Downgrade
JPM logoJJP Morgan
Overweight → Neutral
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Shah GauravOfficerNov 18 '26Proposed Sale2.182,2164,828Nov 18 03:37 PM
Wilson MartinOfficerNov 18 '26Proposed Sale2.186771,475Nov 18 03:25 PM
Shah GauravCEONov 13 '26Sale2.253,0206,7951,053,574Nov 17 05:17 PM
Wilson MartinGeneral CounselNov 13 '26Sale2.254,0879,196541,013Nov 17 05:09 PM
Shah GauravOfficerNov 13 '26Proposed Sale2.253,0206,796Nov 13 04:24 PM
Wilson MartinOfficerNov 13 '26Proposed Sale2.254,0879,197Nov 13 03:53 PM
Chaudhuri SarbaniSee RemarksNov 09 '26Sale2.334,87211,337257,937Nov 12 06:44 PM
Wilson MartinGeneral CounselNov 05 '26Sale2.3953,389127,813545,100Nov 09 04:05 PM
Stevens Christopher JamesOfficerNov 09 '26Proposed Sale2.3316,13137,530Nov 09 03:23 PM
Chaudhuri SarbaniOfficerNov 09 '26Proposed Sale2.334,87211,335Nov 09 03:20 PM
Wilson MartinOfficerNov 05 '26Proposed Sale2.3953,389127,808Nov 05 03:10 PM
Wilson MartinGeneral CounselSep 11 '26Sale3.4075,364256,464598,489Sep 15 08:27 PM
Militello JohnFormer OfficerSep 15 '26Proposed Sale3.306,89722,730Sep 15 04:50 PM
Militello JohnFormer OfficerSep 14 '26Proposed Sale3.326,85722,731Sep 14 03:25 PM
Wilson MartinOfficerSep 11 '26Proposed Sale3.4075,364256,486Sep 11 04:57 PM
Militello JohnFormer OfficerSep 11 '26Proposed Sale3.408,92330,368Sep 11 04:55 PM
Wilson MartinGeneral CounselAug 18 '26Sale3.386312,133673,853Aug 20 05:30 PM
Shah GauravCEOAug 18 '26Sale3.382,2937,7531,056,594Aug 20 05:25 PM
Shah GauravOfficerAug 18 '26Proposed Sale3.382,2937,754Aug 18 03:49 PM
Wilson MartinOfficerAug 18 '26Proposed Sale3.386312,134Aug 18 03:47 PM
Militello JohnFormer OfficerAug 18 '26Proposed Sale3.381,2524,234Aug 18 03:43 PM
Shah GauravCEOAug 13 '26Sale3.382,8379,5921,058,887Aug 17 05:52 PM
Wilson MartinGeneral CounselAug 13 '26Sale3.383,49311,810674,484Aug 17 05:50 PM
Stevens Christopher JamesChief Operating OfficerAug 11 '26Sale3.5036,658128,266505,784Aug 13 04:15 PM
Chaudhuri SarbaniSee RemarksAug 11 '26Sale3.504,70116,449262,809Aug 13 04:15 PM
Wilson MartinOfficerAug 13 '26Proposed Sale3.383,49311,810Aug 13 04:03 PM
Shah GauravOfficerAug 13 '26Proposed Sale3.382,8379,592Aug 13 03:39 PM
Stevens Christopher JamesOfficerAug 11 '26Proposed Sale3.5036,658128,281Aug 11 03:30 PM
Chaudhuri SarbaniOfficerAug 11 '26Proposed Sale3.504,70116,451Aug 11 03:23 PM
Malik Fady IbrahamDirectorJul 07 '26Proposed Sale3.8810,67041,393Jul 07 03:13 PM
Shah GauravCEOMay 21 '26Option Exercise1.6976,490129,3451,117,408May 26 07:47 PM
Shah GauravCEOMay 21 '26Sale3.0955,684171,8411,061,724May 26 07:47 PM
Shah GauravCEOMay 19 '26Sale3.012,4097,2611,040,918May 21 04:06 PM
Wilson MartinGeneral CounselMay 19 '26Sale3.016621,995677,977May 21 04:06 PM
Militello JohnSee RemarksMay 19 '26Sale3.013841,15789,780May 21 04:06 PM
Shah GauravOfficerMay 21 '26Proposed Sale3.0955,684171,821May 21 03:40 PM
Shah GauravOfficerMay 19 '26Proposed Sale3.012,4097,262May 19 03:38 PM
Militello JohnOfficerMay 19 '26Proposed Sale3.013841,158May 19 03:33 PM
Wilson MartinOfficerMay 19 '26Proposed Sale3.016621,996May 19 03:20 PM
Wilson MartinGeneral CounselMay 13 '26Sale3.613,36112,120678,639May 14 04:22 PM
Shah GauravCEOMay 13 '26Sale3.612,7289,8371,043,327May 14 04:19 PM
Militello JohnSee RemarksMay 13 '26Sale3.618553,08390,164May 14 04:16 PM
Wilson MartinOfficerMay 13 '26Proposed Sale3.613,36112,118May 13 03:15 PM
Shah GauravOfficerMay 13 '26Proposed Sale3.612,7289,836May 13 03:13 PM
Militello JohnOfficerMay 13 '26Proposed Sale3.618553,083May 13 03:10 PM
Chaudhuri SarbaniSee RemarksMay 07 '26Sale3.8417,65067,741267,510May 11 07:48 PM
Chaudhuri SarbaniOfficerMay 07 '26Proposed Sale3.8417,65067,741May 07 03:14 PM
Militello JohnSee RemarksFeb 18 '26Sale3.341,1573,86291,019Feb 20 04:31 PM
Shah GauravCEOFeb 18 '26Sale3.345,99019,9951,046,055Feb 20 04:26 PM
Wilson MartinGeneral CounselFeb 18 '26Sale3.341,3764,593682,000Feb 20 04:09 PM
Wilson MartinGeneral CounselFeb 13 '26Sale3.3112,25340,582683,376Feb 18 05:42 PM
Militello JohnSee RemarksFeb 13 '26Sale3.313,72612,34192,176Feb 18 05:38 PM
Shah GauravCEOFeb 13 '26Sale3.3112,27940,6681,052,045Feb 18 05:33 PM
Militello JohnOfficerFeb 18 '26Proposed Sale3.341,1573,863Feb 18 04:58 PM
Wilson MartinOfficerFeb 18 '26Proposed Sale3.341,3764,594Feb 18 04:50 PM
Shah GauravOfficerFeb 18 '26Proposed Sale3.345,99019,998Feb 18 04:50 PM
Wilson MartinOfficerFeb 13 '26Proposed Sale3.3112,25340,583Feb 13 04:31 PM
Shah GauravOfficerFeb 13 '26Proposed Sale3.3112,27940,669Feb 13 03:55 PM
Schwartz Jonathan DavidOfficerFeb 13 '26Proposed Sale3.3114,50848,052Feb 13 03:53 PM
Militello JohnOfficerFeb 13 '26Proposed Sale3.313,72612,341Feb 13 03:39 PM
Bjork ElisabethDirectorJan 02 '26Buy3.4410,00034,40050,000Jan 06 04:05 PM
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. The firm's multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.
CEO & DirectorDr. Gaurav D. Shah M.D.
Gen. CounselMr. Martin Louis Wilson J.D.
Chief Operating OfficerMr. Christopher Stevens
Principal Accounting OfficerMr. Joseph Manhede
Chief Science & Gene Therapy OfficerDr. Jonathan Schwartz M.D.